Gilead Sciences Inc (GILD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,303,000 | -2,556,000 | -4,170,000 | 5,613,000 | 4,196,000 |
| Depreciation Amortization | 2,074,000 | 1,384,000 | 690,000 | 2,693,000 | 2,005,000 |
| Income taxes - deferred | -1,465,000 | -889,000 | -723,000 | -962,000 | -592,000 |
| Accounts receivable | 67,000 | -95,000 | -66,000 | 157,000 | -63,000 |
| Accounts payable and accrued liabilities | 348,000 | -11,000 | 72,000 | -347,000 | -304,000 |
| Other Working Capital | -1,363,000 | -2,005,000 | -459,000 | -2,303,000 | -1,760,000 |
| Other Operating Activity | 9,495,000 | 7,716,000 | 6,875,000 | 3,155,000 | 2,355,000 |
| Operating Cash Flow | $7,853,000 | $3,544,000 | $2,219,000 | $8,006,000 | $5,837,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | 2,348,000 | 2,348,000 | 2,348,000 | -86,000 | -77,000 |
| PPE Investments | -376,000 | -235,000 | -105,000 | -585,000 | -370,000 |
| Net Acquisitions | -4,765,000 | -4,195,000 | -4,043,000 | -1,152,000 | -873,000 |
| Purchase Of Investment | -453,000 | -444,000 | -410,000 | -442,000 | -218,000 |
| Other Investing Activity | 22,000 | 12,000 | 3,000 | 0 | 0 |
| Investing Cash Flow | $-3,224,000 | $-2,514,000 | $-2,207,000 | $-2,265,000 | $-1,538,000 |
| Cash Flows From Financing Activities | |||||
| Debt Issued | 0 | N/A | N/A | 1,980,000 | 1,979,000 |
| Debt Repayment | -1,963,000 | -1,851,000 | N/A | -2,250,000 | -2,250,000 |
| Common Stock Issued | 249,000 | 151,000 | 146,000 | 232,000 | 206,000 |
| Common Stock Repurchased | -800,000 | -500,000 | -400,000 | -1,000,000 | -850,000 |
| Dividend Paid | -2,945,000 | -1,962,000 | -990,000 | -3,809,000 | -2,866,000 |
| Other Financing Activity | -234,000 | -152,000 | -117,000 | -278,000 | -245,000 |
| Financing Cash Flow | $-5,693,000 | $-4,314,000 | $-1,361,000 | $-5,125,000 | $-4,026,000 |
| Exchange Rate Effect | 15,000 | -29,000 | -18,000 | 57,000 | 20,000 |
| Beginning Cash Position | 6,085,000 | 6,085,000 | 6,085,000 | 5,412,000 | 5,412,000 |
| End Cash Position | 5,037,000 | 2,772,000 | 4,718,000 | 6,085,000 | 5,705,000 |
| Net Cash Flow | $-1,049,000 | $-3,313,000 | $-1,367,000 | $673,000 | $293,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 7,853,000 | 3,544,000 | 2,219,000 | 8,006,000 | 5,837,000 |
| Capital Expenditure | -376,000 | -235,000 | -105,000 | -585,000 | -370,000 |
| Free Cash Flow | 7,477,000 | 3,309,000 | 2,114,000 | 7,421,000 | 5,467,000 |